)
Visual
earnings real time
Agomab Therapeutics
Agomab Therapeutics (AGMB) investor relations material
Agomab Therapeutics has been private
Agomab Therapeutics Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary29 Jan, 2026
Company overview and business model
Clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, initially focusing on chronic fibrotic indications with high unmet medical need.
Lead product candidates: ontunisertib (oral, GI-restricted ALK5 inhibitor for fibrostenosing Crohn's disease) and AGMB-447 (inhaled ALK5 inhibitor for idiopathic pulmonary fibrosis).
Pipeline includes preclinical programs and AGMB-101, an HGF-mimetic monoclonal antibody for liver cirrhosis.
Retains exclusive, worldwide development and commercialization rights to all product candidates.
Financial performance and metrics
Reported net losses of €46.3 million in 2024 and €45.1 million for the nine months ended September 30, 2025.
Accumulated loss of €164.3 million as of September 30, 2025.
Cash and cash equivalents of €129.6 million as of September 30, 2025; pro forma as adjusted after IPO, cash and cash equivalents would be €283.2 million.
R&D expenses increased to €39.3 million in 2024 and €35.0 million for the nine months ended September 30, 2025, reflecting clinical progress.
No revenue generated to date; expects continued operating losses for the foreseeable future.
Use of proceeds and capital allocation
Estimated net proceeds of $182 million from the IPO (or $210 million if underwriters exercise their option in full), based on an assumed price of $16.00 per ADS.
Approximately $120 million allocated to advance ontunisertib through a planned global Phase 2b trial in FSCD.
Approximately $80 million allocated to advance AGMB-447 through a planned Phase 2 trial in IPF.
Remainder to fund preclinical candidates, general and administrative expenses, working capital, milestone payment for Origo Biopharma acquisition, and other corporate purposes.
Funds expected to support operations until the first half of 2029.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- QBY
Profitability returns in 2025, driven by sector focus, AI, and international expansion. - NAZARA
EBITDA and margins rose on IP focus, but regulatory changes led to major impairment losses. - HAPPYFORGE
Stable to growing financials, strong margins, and disciplined IPO fund use with no audit concerns. - RBA
Q3 revenue rose 16.5% in India; Inspira Global to acquire a controlling stake and infuse capital. - 6674
Profits and dividends revised upward on strong battery sales and improved margins. - BOROUGE
$1.1B net profit, 37% EBITDA margin, record sales, and major restructuring drive future growth. - 8059
Record Q3 profits and strong segment growth support an upwardly revised full-year outlook. - 7011
Strong order intake and profit growth drive upward revision of FY2025 forecasts and reflect key divestiture impact. - 9101
Profits fell across most segments, but energy shipping and a major acquisition stood out. - 4626
Double-digit sales and profit growth, revised forecasts, and a stock split impact.
Agomab Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage